摘要
目的比较促红细胞生成素(Erythropoietin,EPO)与悬浮红细胞治疗终末期肾病(end-stage renal disease,ESRD)维持性血液透析(maintenance hemodialysis,MHD)患者肾性贫血的临床疗效和不良反应。方法 2010年9月至2012年12月我院收治的ESRD行MHD肾性贫血患者90例,其中45例采用EPO治疗(EPO组),45例输注悬浮红细胞治疗(输血组),比较两组治疗前后红细胞计数、血红蛋白水平变化情况以及不良反应发生率。结果两组临床疗效、不良反应发生率及治疗前后红细胞计数、血红蛋白水平差异均有统计学意义(P<0.05)。结论 EPO治疗肾性贫血患者疗效确切,不良反应较输注悬浮红细胞小,值得临床推广应用。
Objective To compare the clinical efficacy and adverse reactions of suspended red blood cell therapy and erythro-poietin in treatment of kidney anemia. Methods Ninety patients with end-stage renal disease （ESRD） in our hospital from September, 2010 to December, 2012 were stochastically divided into treatment and control group, 45 in each group. The treatment group was treated with erythropoietin （EPO） while the control group was treated with suspended RBC components. The changes of RBC count and hemoglobin level, as well as the rate of adverse reactions before and after treatment were compared between the two groups. Results There were statistical differences in RBC count and hemoglobin level before and after treatment in the two groups （ P 〈 0.05 ）. Moreover, there were statistical differences in rates of curative effects and adverse reactions （ P 〈 0.05 ）. Conclusions It can be concluded that EPO has high curative effect with little adverse reaction in the treatment of kidney anemia. It is worthy of clinical application.
出处
《实用医院临床杂志》
2013年第4期113-115,共3页
Practical Journal of Clinical Medicine
